Wave Life Sciences (WVE) Share-based Compensation (2015 - 2026)
Wave Life Sciences' (WVE) quarterly Share-based Compensation came in at $21.0 million in Q2 2026, up 238.15% YoY from $6.2 million in Q2 2025, and up 131.18% on a QoQ basis from $9.1 million in Q1 2026.
Wave Life Sciences (WVE) Share-based Compensation (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Share-based Compensation data on file, last reported at $21.0 million in Q2 2026.
- Quarterly Share-based Compensation rose 238.15% year-over-year to $21.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.8 million (up 144.58% YoY) and the FY2025 annual result came in at $25.0 million, up 90.04% from the prior year.
- Share-based Compensation grew to $21.0 million in Q2 2026, from $9.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $21.0 million in Q2 2026 to a low of $2.3 million in Q3 2022.
- A 5-year average of $5.3 million and a median of $3.5 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 70.02% — and 2026, when it soared 238.15%.
- Tracing WVE's Share-based Compensation over 5 years: stood at $2.9 million in 2022, then slipped by 19.09% to $2.4 million in 2023, then jumped by 37.93% to $3.2 million in 2024, then jumped by 126.63% to $7.4 million in 2025, then soared by 184.98% to $21.0 million in 2026.
- The last three Share-based Compensation figures came in at $21.0 million (Q2 2026), $9.1 million (Q1 2026), and $7.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 20.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.95 Mn |
| Jun 30, 2026 | 20.95 Mn |
| Mar 31, 2026 | 9.06 Mn |
| Mar 31, 2026 | 9.06 Mn |
| Dec 31, 2025 | 7.35 Mn |
| Dec 31, 2025 | 7.35 Mn |
| Sep 30, 2025 | 6.47 Mn |
| Sep 30, 2025 | 6.47 Mn |
| Jun 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.20 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |